What clinical criteria do you use to decide between antivirals, rituximab, plasmapheresis, or a combination therapy for treating hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis?  

Direct-acting antiviral agents would help eradicate the HCV clone and often the HCV-infected B lymphocytes that produce the polyclonal IgM (III cryo) or monoclonal IgM (II cryo) against IgG. Sometimes, despite HCV clearance, B-cell clones persist, leading to cryoglobulinemic vasculitis and MPGN; in ...